🇺🇸 FDA
Patent

US 11273150

Compositions and methods for the treatment of presbyopia

granted A61KA61K31/439A61K31/4409

Quick answer

US patent 11273150 (Compositions and methods for the treatment of presbyopia) held by Lenz Therapeutics, Inc. expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lenz Therapeutics, Inc.
Grant date
Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/439, A61K31/4409, A61K31/717, A61K45/06